INSUBCONTINENT EXCLUSIVE:
Despite near-miraculous advances in the treatment of cancer in the U.S
and around the world, the disease remains the second leading cause of death in America.The problem is that every manifestation of the
Most cancer treatments are determined by their ability to cure the largest population afflicted with a particular cancer type.As
understanding of the disease has advanced, more targeted treatments are coming to market to treat particular types of the disease
And now, Xilis has developed a process that its founders hope will make those treatments even more effective.Founded by Xiling Shen and Dr
Clevers, who won the Breakthrough Prize for life sciences in 2004 and serves on the board of directors of Roche, helped refine a technique
for growing small versions of human organs for research.Shen and Hsu have taken that research and advanced it, developing a process that can
Their results were so promising that the two decided to form a company around the innovation and raise capital to accelerate the
time-to-clinic so that patients could reap the benefits of these more targeted therapies.Indeed, the technology is so compelling that
the technology, Xilis has raised $3 million in seed funding from investors including Felicis Ventures, an early investor in the
